StockData
Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc. (EVFM) stock

EVFMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.01−0.00 (-10.00%)

Close on Oct 19, 2026Market cap $865.23KP/E –Yield –

Evofem Biosciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Evofem Biosciences's total debt was $362.00K at Jun 30, 2026. For fiscal 2025 it was $147.00K, up 8.9% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$147.00K+8.9%
FY2024Dec 31, 2024$135.00K-98.6%
FY2015Dec 31, 2015$9.96M+2.3%
FY2014Dec 31, 2014$9.74M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$362.00K+168.1%
Q4 FY2025Dec 31, 2025$147.00K-45.1%
Q3 FY2025Sep 30, 2025$291.00K-26.7%
Q2 FY2025Jun 30, 2025$383.00K-90.4%
Q4 FY2024Dec 31, 2024$135.00K–
Q3 FY2024Sep 30, 2024$268.00K–
Q2 FY2024Jun 30, 2024$397.00K–
Q2 FY2016Jun 30, 2016$4.00M–

More Evofem Biosciences figures

See a number that looks wrong?